Does Anavar cause gynaecomastia? It is a question commonly asked by those using or considering oxandrolone for performance enhancement. As a dihydrotestosterone (DHT) derivative, Anavar cannot be converted into oestrogen through aromatisation, which means its direct risk of causing gynaecomastia is lower than many other anabolic steroids. However, it suppresses natural testosterone production, alters the oestrogen-to-androgen ratio, and is frequently sold in counterfeit form — all of which can increase the risk. This article examines the hormonal mechanisms involved, key risk factors, warning signs, when to seek medical advice, and the legal status of oxandrolone in the UK.

How Oxandrolone Affects Hormone Levels in the Body

Oxandrolone cannot aromatise to oestrogen, so it is unlikely to directly cause gynaecomastia, but it suppresses endogenous testosterone via the HPG axis and reduces SHBG, creating an unfavourable hormonal environment that may increase risk.

Oxandrolone (sold under the brand name Anavar) is a synthetic anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). It is occasionally prescribed in clinical settings for conditions such as muscle wasting, severe burns, or recovery from prolonged illness. However, it is widely misused in the UK for performance enhancement and physique modification, often without medical supervision.

As a DHT derivative, oxandrolone is non-aromatisable — it cannot be converted into oestrogen via the aromatase enzyme. Because gynaecomastia (the development of glandular breast tissue in males) is primarily driven by an imbalance between oestrogen and androgen activity, oxandrolone's inability to aromatise means it is unlikely to directly cause gynaecomastia through this mechanism. This distinguishes it from steroids such as testosterone, which aromatise readily.

However, oxandrolone does suppress the body's natural testosterone production through negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis. This suppression lowers endogenous testosterone levels, which may shift the oestrogen-to-androgen ratio unfavourably — particularly when oxandrolone is used in isolation or as part of a poorly planned cycle. Oxandrolone also reduces sex hormone-binding globulin (SHBG) levels, further altering the hormonal environment.

It is also important to note that nandrolone decanoate, a steroid sometimes used alongside oxandrolone, carries a gynaecomastia risk that is primarily due to its progestogenic activity (with some contribution from partial aromatisation), rather than high aromatisation alone.

A further, often overlooked risk is that products sold as 'Anavar' through unregulated sources are frequently counterfeit, mislabelled, or contaminated. Such products may contain aromatisable anabolic steroids, substantially altering the gynaecomastia risk profile. The MHRA has issued repeated warnings about the dangers of purchasing anabolic steroids from unregulated online sources. While there is no definitive clinical evidence establishing a strong direct causal link between genuine oxandrolone alone and gynaecomastia, the hormonal disruption it causes — and the risks associated with counterfeit products — should not be dismissed.

Risk Factors That May Increase the Likelihood of Gynaecomastia

Stacking oxandrolone with aromatisable or progestogenic steroids, using counterfeit products, genetic predisposition, obesity, and pre-existing hormonal imbalances all significantly increase the likelihood of gynaecomastia.

Although oxandrolone carries a lower intrinsic risk of gynaecomastia than many other anabolic steroids, several individual and contextual factors can significantly increase susceptibility. Understanding these risk factors is important for anyone seeking to assess their personal risk profile.

Key risk factors include:

• Stacking with other steroids: Oxandrolone is frequently used alongside higher-aromatising or progestogenic compounds such as testosterone, methandrostenolone, or nandrolone decanoate. These combinations substantially raise circulating oestrogen or progestogenic activity, greatly increasing the risk of gynaecomastia.

• Counterfeit or mislabelled products: As noted above, unregulated 'Anavar' may contain aromatisable steroids, directly raising gynaecomastia risk.

• Pre-existing hormonal imbalances: Individuals with naturally elevated oestrogen levels, reduced androgen sensitivity, or conditions such as hypogonadism may be more vulnerable.

• Genetic predisposition: Some individuals have greater aromatase activity or heightened breast tissue sensitivity to oestrogen, making them more prone to gynaecomastia regardless of the specific compound used.

• Obesity: Excess adipose tissue increases peripheral aromatase activity, raising oestrogen levels and gynaecomastia risk independently of steroid use.

• Systemic illness: Liver disease, chronic kidney disease, and thyroid dysfunction can all alter hormone metabolism and increase gynaecomastia risk.

• Testicular tumours: Certain testicular tumours (including Leydig cell tumours and germ cell tumours) can produce oestrogens or hCG, causing gynaecomastia.

• Age: Adolescents and older men experience natural hormonal fluctuations that can compound the effects of exogenous steroid use.

• Use of other substances: Recreational drugs, alcohol, and certain medicines are independently associated with gynaecomastia. Well-evidenced causative agents include spironolactone, antiandrogens (such as finasteride and bicalutamide), cimetidine, ketoconazole, some antiretrovirals, digoxin, and some antipsychotics. Associations with proton pump inhibitors and antidepressants are reported but are considered rare and of low certainty.

• Prolonged or high-dose use: Extended cycles or supraphysiological doses increase cumulative hormonal disruption.

It is also worth noting that the use of post-cycle therapy (PCT) agents such as selective oestrogen receptor modulators (SERMs) — for example, tamoxifen or clomifene — is common in non-medical steroid use. Whilst these are sometimes used to mitigate gynaecomastia risk, their unsupervised use carries its own health risks and does not eliminate the underlying dangers of steroid misuse.

Recognising the Signs and Symptoms of Gynaecomastia

Gynaecomastia typically presents as a firm, rubbery lump beneath the nipple, breast tenderness, or swelling; red-flag features such as a hard irregular mass, blood-stained nipple discharge, or skin changes require urgent medical assessment.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, and it is distinct from pseudogynaecomastia, which involves fat deposition in the chest area without true glandular proliferation. Recognising the difference is clinically important, as true gynaecomastia involves actual breast tissue growth driven by hormonal changes.

Common signs and symptoms of gynaecomastia include:

• A firm, rubbery, or disc-like lump of tissue felt directly beneath the nipple or areola

• Breast tenderness or sensitivity, particularly around the nipple

• Swelling or enlargement of one or both breasts (unilateral or bilateral)

• Nipple sensitivity or discomfort when clothing rubs against the chest

• In some cases, a small amount of nipple discharge (which warrants prompt medical review)

Gynaecomastia associated with anabolic steroid use typically presents bilaterally, though asymmetric presentations are possible. Early-stage gynaecomastia may be subtle and easily overlooked. If left unaddressed, particularly if the hormonal stimulus persists, the condition can progress from a soft, reversible stage to a more fibrous, permanent form that may ultimately require surgical intervention.

It is important to distinguish gynaecomastia from other causes of breast changes in males, including male breast cancer, which, whilst uncommon, can present similarly. The following features are red flags and require urgent medical assessment:

• A hard, irregular, or fixed lump in the breast

• Skin changes over the breast (such as dimpling or puckering)

• Nipple inversion or retraction

• Blood-stained nipple discharge

• Associated lymph node swelling in the axilla

In line with NICE guidance on suspected cancer (NG12), men aged 50 or over with a unilateral, firm subareolar mass — with or without nipple changes — should be referred urgently via the two-week wait pathway for suspected cancer. A hard, irregular, or fixed mass or blood-stained nipple discharge at any age also warrants urgent assessment. Any new or changing breast lump in a male should be assessed by a healthcare professional promptly, regardless of steroid use history.

When to Seek Medical Advice from a GP or Specialist

Any new breast lump, persistent tenderness, nipple discharge, or rapid breast enlargement warrants prompt GP assessment, including hormone blood tests and, where red-flag features are present, urgent referral under the NICE NG12 two-week wait pathway.

Anyone who notices changes in breast tissue — whether or not they are using anabolic steroids — should seek medical advice without delay. In the UK, GPs are the appropriate first point of contact and can carry out an initial assessment, arrange relevant blood tests, and refer to secondary care if necessary.

You should contact your GP promptly if you experience:

• A new lump or swelling in the breast or chest area

• Breast pain or tenderness that is persistent or worsening

• Any nipple discharge, particularly if blood-stained

• Rapid or progressive breast enlargement

• Symptoms accompanied by other hormonal changes, such as reduced libido, erectile dysfunction, fatigue, or mood disturbance

In clinical practice, investigation of gynaecomastia typically includes a thorough history, physical examination, and blood tests to assess hormone levels — including testosterone, luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol, prolactin, and thyroid function. Liver function tests may also be requested, as hepatic dysfunction can contribute to altered hormone metabolism. Where a testicular tumour is suspected, examination of the testes and measurement of serum hCG (and, where indicated, alpha-fetoprotein) should be performed; testicular ultrasound may be arranged if clinically indicated. Breast ultrasound or other imaging may also be arranged to characterise breast tissue further. This approach is consistent with NICE CKS guidance on gynaecomastia.

It is essential to be honest with your GP about any use of anabolic steroids or other performance-enhancing drugs. Healthcare professionals are bound by confidentiality and their primary concern is your health and safety. Withholding this information can lead to delayed or incorrect diagnosis.

If gynaecomastia is confirmed and is causing significant physical or psychological distress, referral to an endocrinologist or plastic surgeon may be appropriate. Where red-flag features are present, urgent referral under the NICE NG12 two-week wait pathway for suspected cancer should be arranged. NICE guidance supports a patient-centred approach to management, which may include watchful waiting, medical treatment, or surgical correction depending on the stage and severity.

Legal Status and Health Risks of Oxandrolone in the UK

Oxandrolone is a Class C controlled substance in the UK; supply, postal importation, and possession with intent to supply are criminal offences, and non-medical use carries serious risks including cardiovascular harm, hepatotoxicity, and prolonged hypogonadism.

In the United Kingdom, oxandrolone is classified as a Class C controlled substance under the Misuse of Drugs Act 1971 and is listed under Schedule 4 Part II of the Misuse of Drugs Regulations 2001. It is also a prescription-only medicine under the Human Medicines Regulations 2012.

Under UK law, it is illegal to supply oxandrolone or any anabolic steroid, to possess it with intent to supply, or to import or export it by post or courier. Personal possession of anabolic steroids for one's own use is not generally a criminal offence in the UK, although personal importation must be carried out in person (not by post or courier). Anyone considering their legal position should refer to current GOV.UK and Home Office guidance, as penalties for supply-related offences are significant. The MHRA has issued repeated warnings about the dangers of purchasing anabolic steroids from unregulated online sources, where products are frequently counterfeit, contaminated, or mislabelled.

Beyond the legal implications, the health risks associated with non-medical oxandrolone use are considerable and extend well beyond gynaecomastia:

• Cardiovascular effects: Oxandrolone adversely affects lipid profiles, lowering HDL ('good') cholesterol and raising LDL ('bad') cholesterol, increasing the risk of atherosclerosis and cardiovascular events.

• Hepatotoxicity: As a 17-alpha alkylated oral steroid, oxandrolone is processed by the liver and can cause hepatic stress, elevated liver enzymes, and, in severe cases, peliosis hepatis or cholestasis.

• Endocrine disruption: Suppression of the HPG axis can result in prolonged hypogonadism, infertility, and testicular atrophy, some of which may not fully reverse after cessation.

• Psychological effects: Mood disturbances, aggression, and dependency have been reported with anabolic steroid use.

• Adolescent-specific risks: Use during adolescence can prematurely close growth plates, resulting in stunted height.

If you believe you have experienced a side effect from any medicine or substance, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

The NHS does not endorse the use of anabolic steroids for performance enhancement or aesthetic purposes. Individuals concerned about their use of oxandrolone or other anabolic steroids are encouraged to speak with their GP or contact Frank (www.talktofrank.com), the UK's national drug information service, for confidential advice and support.

Frequently Asked Questions